Abstract library

7 results for "Doglioni".
#364 Platinum-based chemotherapy in patients with advanced neuroendocrine carcinomas: an Italian retrospective multicenter analysis
Introduction: Conventional chemotherapy has not yet a well defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs).
Conference:
Category: Basic
Presenting Author: MD FRANCESCA SPADA
Authors:
#1514 Number and Localization of Positive Lymph Nodes Correlate with Recurrence in Nonfunctioning Pancreatic Neuroendocrine Neoplasms: Implications for Surgery, Staging and Surveillance
Introduction: Lymph Nodes involvement is a powerful prognostic factor for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PNEN)
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Stefano Partelli
Authors:
Keywords: PNEN, nodes
#1863 Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: A Case-Matched Analysis
Introduction: Neoadjuvant Peptide receptor radionuclide therapy (NPRRT) can be an option for advanced pancreatic neuroendocrine neoplasms (PNEN) before surgery. Is not clear if NPRRT increases postoperative morbidity
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Francesca Muffatti
Authors:
#2096 The Number of Positive Nodes Accurately Predicts Recurrence after Pancreaticoduodenectomy for Nonfunctioning Neuroendocrine Neoplasms
Introduction: The presence of lymph node metastases is one of the most powerful predictor of recurrence after surgery for pancreatic neuroendocrine neoplasms (PanNENs), but the most appropriate nodal staging for PanNENs is unclear.
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: Valentina Andreasi
Authors:
#2200 Tumor Size Correlates with Grading in Nonfunctioning Pancreatic Neuroendocrine Tumors and Is Not Age-Dependent
Introduction: Tumor growth and Ki67 value increase are associated with aggressiveness in nonfunctioning pancreatic neuroendocrine tumours (NF-PanNET), but their natural history is largely unknown. It is unknown if the evolution of NF-PanNET is time-dependant.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Francesca Muffatti
Authors:
#2276 Ki-67 to Predict Recurrence and Survival of Pancreatic Neuroendocrine Tumors
Introduction: Despite evidence of different malignant potential, postoperative follow-up is similar for G1 and G2 pancreatic neuroendocrine tumors (panNET) and adjuvant treatment is currently not indicated.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: M.D. Cansu Genc
Authors:
#2278 Incidental Histological Diagnosis of Small Pancreatic Neuroendocrine Tumors: Are We Underestimating Their Incidence?
Introduction: The annual incidence of pancreatic neuroendocrine tumours (PanNET) has been estimated to be around 0.8/100,000 inhabitants.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. Fabio Giannone
Authors: